8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Feb 25, 2026·SEC
Veracyte, Inc.(VCYT)Earnings, Financials & Key Ratios
VCYT•NASDAQ
65.4× P/E·Price updated Jun 19, 2026
AboutVeracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Show more
- Revenue$517M+16.0%
- EBITDA$96M+141.3%
- Net Income$66M+174.9%
- EPS (Diluted)0.82+164.5%
- Gross Margin69.62%+4.1%
- EBITDA Margin18.48%+108.0%
- Operating Margin14.34%+296.0%
- Net Margin12.83%+136.9%
- ROE5.34%+145.5%
VCYT Key Insights
Veracyte, Inc. (VCYT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 24.5% free cash flow margin
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 34.5%
✗Weaknesses
- ✗Weak 3Y average ROE of 0.2%
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VCYT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VCYT Price & Volume
Veracyte, Inc. (VCYT) stock price & volume — 10-year historical chart
Loading chart...
VCYT Growth Metrics
Veracyte, Inc. (VCYT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years26.44%
5 Years34.5%
3 Years20.37%
TTM16.91%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM166.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM164.09%
Return on Capital
10 Years-13.13%
5 Years-2.99%
3 Years-0.27%
Last Year5.78%
VCYT Recent Earnings
Veracyte, Inc. (VCYT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.52+52.9%
$0.34
Rev
$139M+6.7%
$130M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.53+29.8%
$0.41
Rev
$141M+3.6%
$136M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.51+59.4%
$0.32
Rev
$132M-2.9%
$136M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.44+41.9%
$0.31
Rev
$130M+4.7%
$124M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.52vs $0.34+52.9% | $139Mvs $130M+6.7% |
| Q1 2026 | Feb 25, 2026 | $0.53vs $0.41+29.8% | $141Mvs $136M+3.6% |
| Q4 2025 | Nov 4, 2025 | $0.51vs $0.32+59.4% | $132Mvs $136M-2.9% |
| Q3 2025 | Aug 6, 2025 | $0.44vs $0.31+41.9% | $130Mvs $124M+4.7% |
Based on last 12 quarters of dataView full earnings history →
VCYT Peer Comparison
Veracyte, Inc. (VCYT) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 ACNB | 592.43M | 57.22 | 15.89 | 28.89% | 19.43% | 9.2% | 0.78 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 |
Compare VCYT vs Peers
Veracyte, Inc. (VCYT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VCYT Income Statement
Veracyte, Inc. (VCYT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 71.95M | 92.01M | 120.37M | 117.48M | 219.51M | 296.54M | 361.05M | 445.76M | 517.14M | 541.74M |
Revenue Growth % | 10.55% | 27.87% | 30.82% | -2.4% | 86.85% | 35.09% | 21.76% | 23.46% | 16.01% | 16.91% |
Cost of Goods Sold | 28.2M | 33.08M | 36.52M | 41.45M | 74.4M | 101.58M | 112.9M | 147.62M | 157.1M | 154.85M |
COGS % of Revenue | 39.19% | 35.95% | 30.34% | 35.29% | 33.89% | 34.26% | 31.27% | 33.12% | 30.38% | - |
Gross Profit | 43.76M▲ 0% | 58.93M▲ 34.7% | 83.84M▲ 42.3% | 76.03M▼ 9.3% | 145.11M▲ 90.9% | 194.95M▲ 34.3% | 248.15M▲ 27.3% | 298.14M▲ 20.1% | 360.05M▲ 20.8% | 386.89M▲ 0% |
Gross Margin % | 60.81% | 64.05% | 69.66% | 64.71% | 66.11% | 65.74% | 68.73% | 66.88% | 69.62% | 71.42% |
Gross Profit Growth % | 10.44% | 34.67% | 42.28% | -9.32% | 90.87% | 34.35% | 27.29% | 20.15% | 20.76% | - |
Operating Expenses | 70.3M | 81.16M | 98.97M | 111.42M | 227.02M | 236.03M | 333.94M | 282M | 285.89M | 320.05M |
OpEx % of Revenue | 97.7% | 88.21% | 82.22% | 94.84% | 103.42% | 79.6% | 92.49% | 63.26% | 55.28% | - |
Selling, General & Admin | 55.35M | 65.28M | 82.72M | 89.12M | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M | 202.62M |
SG&A % of Revenue | 76.92% | 70.95% | 68.72% | 75.86% | 82.54% | 58.7% | 51.03% | 46.22% | 40.79% | - |
Research & Development | 13.88M | 14.82M | 14.85M | 17.2M | 29.84M | 40.6M | 57.3M | 69.29M | 70.81M | 80.19M |
R&D % of Revenue | 19.29% | 16.11% | 12.34% | 14.64% | 13.59% | 13.69% | 15.87% | 15.54% | 13.69% | - |
Other Operating Expenses | 476K | 1.2M | 1.4M | 5.09M | 15.98M | 21.35M | 92.41M | 6.67M | 4.13M | 3M |
Operating Income | -26.54M▲ 0% | -22.23M▲ 16.2% | -15.13M▲ 32.0% | -35.39M▼ 133.9% | -81.9M▼ 131.4% | -41.08M▲ 49.8% | -85.8M▼ 108.8% | 16.14M▲ 118.8% | 74.15M▲ 359.4% | 66.26M▲ 0% |
Operating Margin % | -36.88% | -24.16% | -12.57% | -30.12% | -37.31% | -13.85% | -23.76% | 3.62% | 14.34% | 12.23% |
Operating Income Growth % | 7.86% | 16.22% | 31.96% | -133.95% | -131.44% | 49.84% | -108.84% | 118.81% | 359.36% | - |
EBITDA | -22.7M | -18.31M | -11.01M | -27.45M | -60.68M | -11.83M | -58.61M | 39.6M | 95.56M | 82.32M |
EBITDA Margin % | -31.54% | -19.9% | -9.15% | -23.36% | -27.64% | -3.99% | -16.23% | 8.88% | 18.48% | 15.19% |
EBITDA Growth % | 10.26% | 19.32% | 39.88% | -149.27% | -121.09% | 80.5% | -395.28% | 167.57% | 141.32% | 75.39% |
D&A (Non-Cash Add-back) | 3.84M | 3.92M | 4.12M | 7.94M | 21.23M | 29.25M | 27.19M | 23.46M | 21.41M | 16.05M |
EBIT | -27.6M | -21.04M | -11.92M | -34.68M | -81.41M | -36.23M | -76.6M | 25.75M | 68.2M | 60.77M |
Net Interest Income | -4.94M | -1.96M | 2.35M | 365K | -106K | 1.77M | 7.33M | 11.15M | 0 | 6.42M |
Interest Income | 0 | 0 | 3.02M | 594K | 135K | 1.97M | 7.34M | 11.15M | 0 | 6.42M |
Interest Expense | 4.94M | 1.96M | 677K | 229K | 241K | 198K | 15K | 2K | 0 | 0 |
Other Income/Expense | -4.46M | -766K | 2.53M | 480K | 254K | 4.65M | 9.18M | 9.6M | -5.95M | 24.48M |
Pretax Income | -31M▲ 0% | -23M▲ 25.8% | -12.6M▲ 45.2% | -34.91M▼ 177.1% | -81.65M▼ 133.9% | -36.43M▲ 55.4% | -76.61M▼ 110.3% | 25.74M▲ 133.6% | 68.2M▲ 164.9% | 90.75M▲ 0% |
Pretax Margin % | -43.09% | -25% | -10.47% | -29.71% | -37.2% | -12.28% | -21.22% | 5.78% | 13.19% | 16.75% |
Income Tax | 0 | 0 | 0 | 0 | -6.09M | 133K | -2.21M | 1.61M | 1.85M | 2.73M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 7.45% | -0.37% | 2.88% | 6.24% | 2.71% | 3.01% |
Net Income | -31M▲ 0% | -23M▲ 25.8% | -12.6M▲ 45.2% | -34.91M▼ 177.1% | -75.56M▼ 116.5% | -36.56M▲ 51.6% | -74.4M▼ 103.5% | 24.14M▲ 132.4% | 66.35M▲ 174.9% | 88.01M▲ 0% |
Net Margin % | -43.09% | -25% | -10.47% | -29.71% | -34.42% | -12.33% | -20.61% | 5.42% | 12.83% | 16.25% |
Net Income Growth % | 1.13% | 25.82% | 45.22% | -177.08% | -116.46% | 51.62% | -103.51% | 132.44% | 174.89% | 166.31% |
Net Income (Continuing) | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M | 88.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.91▲ 0% | -0.62▲ 31.9% | -0.27▲ 56.5% | -0.66▼ 144.4% | -1.11▼ 68.2% | -0.51▲ 54.1% | -1.02▼ 100.0% | 0.31▲ 130.4% | 0.82▲ 164.5% | 1.08▲ 0% |
EPS Growth % | 16.51% | 31.87% | 56.45% | -144.44% | -68.18% | 54.05% | -100% | 130.39% | 164.52% | 164.09% |
EPS (Basic) | -0.91 | -0.62 | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.32 | 0.84 | - |
Diluted Shares Outstanding | 33.93M | 37.02M | 46.14M | 53.24M | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M | 81.31M |
Basic Shares Outstanding | 33.93M | 37.02M | 46.14M | 53.24M | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M | 79.54M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VCYT Balance Sheet
Veracyte, Inc. (VCYT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 53.93M | 96.95M | 187.69M | 375.68M | 243.1M | 248.64M | 285.62M | 372.27M | 488.38M | 522.17M |
Cash & Short-Term Investments | 33.89M | 78M | 159.32M | 349.36M | 177.16M | 178.85M | 216.45M | 289.44M | 412.89M | 439.06M |
Cash Only | 33.89M | 78M | 159.32M | 349.36M | 173.2M | 154.25M | 216.45M | 239.09M | 362.58M | 263.14M |
Short-Term Investments | 0 | 0 | 0 | 0 | 3.96M | 24.61M | 0 | 50.35M | 50.31M | 175.92M |
Accounts Receivable | 12.72M | 13.17M | 19.33M | 18.46M | 41.46M | 44.02M | 40.38M | 46.52M | 44.66M | 50.11M |
Days Sales Outstanding | 64.51 | 52.24 | 58.61 | 57.36 | 68.94 | 54.18 | 40.82 | 38.1 | 31.52 | 32.58 |
Inventory | 5.32M | 3.4M | 6.81M | 4.66M | 11.22M | 14.29M | 16.13M | 21.75M | 20.55M | 0 |
Days Inventory Outstanding | 68.92 | 37.54 | 68.02 | 41 | 55.07 | 51.36 | 52.14 | 53.78 | 47.74 | 38.83 |
Other Current Assets | 2M | 0 | 0 | 0 | -3.96M | 11.47M | 12.66M | 14.55M | 10.28M | 33M |
Total Non-Current Assets | 24.74M | 23.69M | 87.53M | 81.48M | 944.72M | 907.79M | 829.28M | 927.77M | 917.64M | 914.23M |
Property, Plant & Equipment | 9.69M | 8.94M | 17.74M | 16.83M | 31.14M | 30.86M | 30.86M | 71.14M | 58.79M | 58.52M |
Fixed Asset Turnover | 7.43x | 10.29x | 6.78x | 6.98x | 7.05x | 9.61x | 11.70x | 6.27x | 8.80x | 9.39x |
Goodwill | 1.06M | 1.06M | 2.73M | 2.73M | 707.9M | 695.89M | 702.98M | 745.8M | 767.15M | 767.15M |
Intangible Assets | 13.07M | 12M | 65.02M | 59.92M | 202.73M | 174.87M | 88.59M | 102.3M | 89.15M | 85.86M |
Long-Term Investments | 603K | 603K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.64M |
Other Non-Current Assets | 929K | 1.69M | 2.04M | 2M | 2.95M | 6.17M | 6.85M | 8.53M | 2.55M | 2.69M |
Total Assets | 78.67M▲ 0% | 120.64M▲ 53.3% | 275.21M▲ 128.1% | 457.16M▲ 66.1% | 1.19B▲ 159.8% | 1.16B▼ 2.6% | 1.11B▼ 3.6% | 1.3B▲ 16.6% | 1.41B▲ 8.2% | 1.44B▲ 0% |
Asset Turnover | 0.91x | 0.76x | 0.44x | 0.26x | 0.18x | 0.26x | 0.32x | 0.34x | 0.37x | 0.39x |
Asset Growth % | -22.14% | 53.35% | 128.13% | 66.11% | 159.83% | -2.64% | -3.59% | 16.6% | 8.15% | 33.52% |
Total Current Liabilities | 12.03M | 13.06M | 17.47M | 16.78M | 64.15M | 62.61M | 61.24M | 78.63M | 59.94M | 56.12M |
Accounts Payable | 3.85M | 2.52M | 2.33M | 3.12M | 12.36M | 11.91M | 12.94M | 8.63M | 4.59M | 6.91M |
Days Payables Outstanding | 49.88 | 27.76 | 23.27 | 27.44 | 60.64 | 42.8 | 41.84 | 21.35 | 10.67 | 16.77 |
Short-Term Debt | 0 | 1.36M | 0 | 0 | 1.13M | 0 | 0 | 0 | 4.05M | 4.35M |
Deferred Revenue (Current) | 0 | 0 | 0 | 371K | 4.65M | 2.61M | 2.01M | 1.67M | 1.16M | 3.78M |
Other Current Liabilities | 0 | 0 | 10.1M | 9.2M | 33.7M | 36.88M | 29.19M | 47.59M | 50.13M | 44.11M |
Current Ratio | 4.48x | 7.42x | 10.74x | 22.39x | 3.79x | 3.97x | 4.66x | 4.73x | 8.15x | 9.31x |
Quick Ratio | 4.04x | 7.16x | 10.35x | 22.11x | 3.61x | 3.74x | 4.40x | 4.46x | 7.81x | 9.31x |
Cash Conversion Cycle | 83.55 | 62.01 | 103.36 | 70.92 | 63.37 | 62.75 | 51.12 | 70.53 | 68.59 | 54.64 |
Total Non-Current Liabilities | 29.42M | 27.82M | 18.29M | 19.15M | 27.16M | 18.61M | 9.56M | 45.44M | 36.51M | 35.88M |
Long-Term Debt | 24.94M | 23.93M | 694K | 810K | 0 | 0 | 0 | 0 | 0 | 34.99M |
Capital Lease Obligations | 308K | 0 | 11.51M | 9.92M | 14.1M | 10.65M | 7.53M | 43.24M | 35.6M | 116.01M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 5.59M | 4.53M | 734K | 1.23M | 646K | 3.8M |
Other Non-Current Liabilities | 4.17M | 3.9M | 6.09M | 7.59M | 7.13M | 3.43M | 1.3M | 972K | 257K | 257K |
Total Liabilities | 41.44M | 40.88M | 35.76M | 35.93M | 91.31M | 81.22M | 70.8M | 124.07M | 96.44M | 91.99M |
Total Debt | 25.25M | 25.28M | 13.61M | 12.32M | 18.85M | 14.72M | 12.63M | 50.74M | 39.65M | 39.33M |
Net Debt | -8.64M | -52.71M | -145.71M | -337.05M | -154.34M | -139.53M | -203.82M | -188.35M | -322.92M | -223.8M |
Debt / Equity | 0.68x | 0.32x | 0.06x | 0.03x | 0.02x | 0.01x | 0.01x | 0.04x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | 1.28x | 0.41x | 0.48x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -4.76x | -3.38x | -2.72x |
Interest Coverage | -5.59x | -10.72x | -17.61x | -151.44x | -337.79x | -182.97x | -5106.47x | 12873.00x | - | - |
Total Equity | 37.23M▲ 0% | 79.75M▲ 114.3% | 239.46M▲ 200.2% | 421.23M▲ 75.9% | 1.1B▲ 160.3% | 1.08B▼ 1.9% | 1.04B▼ 2.9% | 1.18B▲ 12.6% | 1.31B▲ 11.4% | 1.34B▲ 0% |
Equity Growth % | -37.52% | 114.25% | 200.24% | 75.91% | 160.31% | -1.94% | -2.89% | 12.63% | 11.36% | 38.63% |
Book Value per Share | 1.10 | 2.15 | 5.19 | 7.91 | 16.15 | 15.03 | 14.37 | 15.05 | 16.25 | 16.53 |
Total Shareholders' Equity | 37.23M | 79.75M | 239.46M | 421.23M | 1.1B | 1.08B | 1.04B | 1.18B | 1.31B | 1.34B |
Common Stock | 34K | 41K | 50K | 58K | 71K | 72K | 73K | 78K | 79K | 80K |
Retained Earnings | -211.09M | -234.09M | -246.69M | -281.59M | -357.16M | -393.72M | -468.12M | -443.98M | -377.63M | -348.92M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -9.3M | -12.01M | 0 | 0 | -15.08M | -31.35M | -24.02M | -36.09M | -8.21M | -8.22M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VCYT Cash Flow Statement
Veracyte, Inc. (VCYT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -23.91M | -13.52M | -3.23M | -9.71M | -31.62M | 7.54M | 44.22M | 75.1M | 136.31M | 166.16M |
Operating CF Margin % | -33.24% | -14.7% | -2.69% | -8.27% | -14.41% | 2.54% | 12.25% | 16.85% | 26.36% | - |
Operating CF Growth % | 14.53% | 43.46% | 76.1% | -200.46% | -225.62% | 123.83% | 486.89% | 69.82% | 81.51% | 734.17% |
Net Income | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M | 88.01M |
Depreciation & Amortization | 3.84M | 3.92M | 4.12M | 7.94M | 19.59M | 25.93M | 27.19M | 23.46M | 21.41M | 21.48M |
Stock-Based Compensation | 6.62M | 5.96M | 9.81M | 12.99M | 22.52M | 26.73M | 33.14M | 36.25M | 43.6M | 45.4M |
Deferred Taxes | 12K | 0 | -23K | 0 | -6.26M | 133K | -3.84M | -233K | -581K | -606K |
Other Non-Cash Items | 2.06M | 251K | 312K | 4.74M | 3.87M | 7.68M | 66.3M | 12.8M | 7.82M | -9.24M |
Working Capital Changes | -5.44M | -651K | -4.85M | -481K | 4.22M | -16.38M | -4.16M | -21.32M | -2.3M | 13.08M |
Change in Receivables | -3.96M | -452K | -6.16M | 955K | -8.57M | -4.5M | 3.89M | -6.41M | -708K | 778K |
Change in Inventory | -1.85M | 1.92M | -3.4M | 1.06M | -1.46M | -3.01M | -1.69M | -5.87M | -2.86M | -563K |
Change in Payables | 1.73M | -1.57M | -141K | 711K | 5.16M | 152K | -134K | -4.3M | -1.04M | -5.57M |
Cash from Investing | -1.2M | -1.87M | -42.73M | -3.84M | -739.21M | -29.39M | 15.11M | -56.27M | -9.21M | -85.35M |
Capital Expenditures | -1.75M | -1.87M | -2.76M | -2.84M | -5.38M | -8.55M | -9.96M | -11.29M | -9.68M | -10.82M |
CapEx % of Revenue | 2.44% | 2.04% | 2.29% | 2.41% | 2.45% | 2.88% | 2.76% | 2.53% | 1.87% | 2% |
Acquisitions | 440K | 0 | -40M | 0 | -736.83M | 0 | 0 | 5.01M | -2.85M | -2.85M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 560K | 0 | 23K | 0 | -162.42M | 0 | 0 | 0 | 0 | 51.06M |
Cash from Financing | -218K | 59.5M | 127.29M | 203.59M | 596.32M | 3.49M | 2.84M | 4.9M | -4.22M | -4.37M |
Debt Issued (Net) | -2.31M | -292K | -25.21M | -100K | 0 | -1.28M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 200K | 55.04M | 137.85M | 193.83M | 593.82M | 0 | 0 | 19.99M | 14.08M | 9.3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.9M | 4.75M | 14.65M | 9.86M | 2.5M | 4.78M | 2.84M | -15.09M | -18.3M | -13.67M |
Net Change in Cash | -25.33M▲ 0% | 44.1M▲ 274.1% | 81.32M▲ 84.4% | 190.05M▲ 133.7% | -176.02M▼ 192.6% | -18.95M▲ 89.2% | 62.33M▲ 428.9% | 23.3M▼ 62.6% | 123.59M▲ 430.4% | 77.05M▲ 0% |
Free Cash Flow | -25.67M▲ 0% | -15.39M▲ 40.0% | -5.99M▲ 61.1% | -12.55M▼ 109.6% | -37M▼ 194.8% | -1.01M▲ 97.3% | 34.26M▲ 3478.8% | 63.81M▲ 86.2% | 126.63M▲ 98.5% | 154.81M▲ 0% |
FCF Margin % | -35.68% | -16.73% | -4.97% | -10.68% | -16.85% | -0.34% | 9.49% | 14.31% | 24.49% | 28.58% |
FCF Growth % | 20.26% | 40.03% | 61.1% | -109.55% | -194.84% | 97.26% | 3478.8% | 86.24% | 98.45% | 97.33% |
FCF per Share | -0.76 | -0.42 | -0.13 | -0.24 | -0.54 | -0.01 | 0.47 | 0.82 | 1.57 | 1.90 |
FCF Conversion (FCF/Net Income) | 0.77x | 0.59x | 0.26x | 0.28x | 0.42x | -0.21x | -0.59x | 3.11x | 2.05x | 1.76x |
Interest Paid | 2.72M | 1.55M | 332K | 13K | 9K | 9K | 0 | 0 | 0 | 0 |
Taxes Paid | 21K | 79K | 35K | 112K | 112K | 570K | 1.7M | 2.24M | 0 | 1.43M |
VCYT Key Ratios
Veracyte, Inc. (VCYT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -64.05% | -39.32% | -7.89% | -10.57% | -9.96% | -3.37% | -7.02% | 2.17% | 5.34% | 6.86% |
Return on Invested Capital (ROIC) | -73.1% | -59.96% | -18.79% | -29.83% | -11.97% | -3.28% | -7.25% | 1.32% | 5.63% | 4.8% |
Gross Margin | 60.81% | 64.05% | 69.66% | 64.71% | 66.11% | 65.74% | 68.73% | 66.88% | 69.62% | 71.42% |
Net Margin | -43.09% | -25% | -10.47% | -29.71% | -34.42% | -12.33% | -20.61% | 5.42% | 12.83% | 16.25% |
Debt / Equity | 0.68x | 0.32x | 0.06x | 0.03x | 0.02x | 0.01x | 0.01x | 0.04x | 0.03x | 0.03x |
Interest Coverage | -5.59x | -10.72x | -17.61x | -151.44x | -337.79x | -182.97x | -5106.47x | 12873.00x | - | - |
FCF Conversion | 0.77x | 0.59x | 0.26x | 0.28x | 0.42x | -0.21x | -0.59x | 3.11x | 2.05x | 1.76x |
Revenue Growth | 10.55% | 27.87% | 30.82% | -2.4% | 86.85% | 35.09% | 21.76% | 23.46% | 16.01% | 16.91% |
Related:VCYT Dividend History·VCYT Revenue History·VCYT Price History·VCYT P/E History·VCYT Financial Ratios·VCYT Institutional Holders
VCYT SEC Filings & Documents
Veracyte, Inc. (VCYT) SEC filings — annual & quarterly reports (10-K, 10-Q)
VCYT Frequently Asked Questions
Veracyte, Inc. (VCYT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Veracyte, Inc. (VCYT) reported $541.7M in revenue for fiscal year 2025. This represents a 20382% increase from $2.6M in 2011.
Veracyte, Inc. (VCYT) grew revenue by 16.0% over the past year. This is strong growth.
Yes, Veracyte, Inc. (VCYT) is profitable, generating $88.0M in net income for fiscal year 2025 (12.8% net margin).
Dividend & Returns
Veracyte, Inc. (VCYT) has a return on equity (ROE) of 5.3%. This is below average, suggesting room for improvement.
Veracyte, Inc. (VCYT) generated $154.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.